ArticleTuberculosis and respiratory diseases2026
A Multicenter Registry for Rare Interstitial Lung Diseases in Korea: Baseline Characteristics and Clinical Outcomes.
Article in Tuberculosis and respiratory diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundRare interstitial lung diseases (ILDs) are a heterogeneous group of diffuse parenchymal lung disorders with low prevalence and diverse etiologies that pose diagnostic and therapeutic challenges. We aimed to establish a nationwide, multicenter registry of rare ILDs in South Korea to characterize their clinical features and outcomes.
methodsWe conducted a multicenter, observational cohort study involving 304 patients with rare ILDs including Birt-Hogg-Dubé syndrome (BHD), lymphangioleiomyomatosis (LAM), pulmonary alveolar proteinosis (PAP), pulmonary Langerhans cell histiocytosis (PLCH), pleuroparenchymal fibroelastosis (PPFE), and hypersensitivity pneumonitis (HP) enrolled across 20 centers in Korea between September 2023 and December 2024. Data on clinical characteristics, outcomes, and treatment were collected.
resultsLAM (28.3%) and PAP (26.6%) were the most prevalent, followed by BHD (18.1%), PLCH (13.2%), HP (7.6%), and PPFE (6.3%). Dyspnea was common in HP and PPFE, whereas BHD and LAM were often asymptomatic. Pneumothorax was frequent in BHD (44.6%) and LAM (11.6%) at diagnosis. PPFE showed the most impaired lung function and the highest mortality (26.3%), during a median follow-up of 69.5 months, followed by PAP (6.2%) and BHD (1.8%). During follow-up, cancer was reported in 25.5% of patients with BHD. Treatment strategies varied by disease: corticosteroids were commonly used in HP (86.9%), PPFE (42.1%), and PLCH (32.5%); sirolimus in LAM (53.5%); pirfenidone in PPFE (42.1%); and whole-lung lavage in PAP (23.5%).
conclusionThis is the first nationwide rare ILD registry in Korea, demonstrating heterogeneity in clinical features and outcomes and emphasizing the need for disease-specific diagnostic and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.